跳转至内容
Merck
CN

49322

NMP

puriss. p.a., ≥99.0% (GC)

别名:

N-甲基-2-吡咯烷酮, N-甲基吡咯烷酮, NMP

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C5H9NO
化学文摘社编号:
872-50-4
分子量:
99.13
UNSPSC Code:
12352005
PubChem Substance ID:
329757410
EC Number:
212-828-1
Beilstein/REAXYS Number:
106420
MDL number:
MFCD00003193
Assay:
≥99.0% (GC)
Technique(s):
GC/GC: suitable
Bp:
202 °C (lit.)
81-82 °C/10 mmHg (lit.)
Vapor pressure:
0.29 mmHg ( 20 °C)
0.99 mmHg ( 40 °C)

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

1-甲基-2-吡咯烷酮, puriss. p.a., ≥99.0% (GC)

InChI key

SECXISVLQFMRJM-UHFFFAOYSA-N

InChI

1S/C5H9NO/c1-6-4-2-3-5(6)7/h2-4H2,1H3

SMILES string

CN1CCCC1=O

vapor density

3.4 (vs air)

vapor pressure

0.29 mmHg ( 20 °C)
0.99 mmHg ( 40 °C)

grade

puriss. p.a.

assay

≥99.0% (GC)

form

liquid

autoignition temp.

518 °F

expl. lim.

9.5 %

technique(s)

GC/GC: suitable

impurities

≤0.1% water

refractive index

n20/D 1.47 (lit.)
n20/D 1.470

pH

7.7-8

bp

202 °C (lit.)
81-82 °C/10 mmHg (lit.)

mp

−24 °C (lit.)

density

1.028 g/mL at 25 °C (lit.)

cation traces

Ca: ≤5 mg/kg
Cd: ≤1 mg/kg
Co: ≤1 mg/kg
Cr: ≤1 mg/kg
Cu: ≤1 mg/kg
Fe: ≤1 mg/kg
K: ≤20 mg/kg
Mg: ≤1 mg/kg
Mn: ≤1 mg/kg
Na: ≤20 mg/kg
Ni: ≤1 mg/kg
Pb: ≤1 mg/kg
Zn: ≤1 mg/kg

Quality Level

100

正在寻找类似产品? 访问 产品对比指南

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 1

flash_point_f

195.8 °F - Pensky-Martens closed cup

flash_point_c

91 °C - Pensky-Martens closed cup

ppe

Eyeshields, Gloves, type ABEK (EN14387) respirator filter

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

B A Jönsson et al.
Journal of chromatography. B, Biomedical sciences and applications, 694(2), 351-357 (1997-07-04)
A method for simultaneous determination of 5-hydroxy-N-methylpyrrolidone and 2-hydroxy-N-methylsuccinimide in urine is described. These compounds are metabolites of N-methyl-2-pyrrolidone, a powerful and widely used organic solvent. 5-Hydroxy-N-methylpyrrolidone and 2-hydroxy-N-methylsuccinimide were purified from urine by adsorption to a C8 solid-phase extraction
Laura Vogelaar et al.
Small (Weinheim an der Bergstrasse, Germany), 1(6), 645-655 (2006-12-29)
Phase separation micromolding (PSmicroM) is a versatile microfabrication technique that can be used to structure a very broad range of polymers, including block copolymers and biodegradable and conductive polymers without the need for clean-room facilities. By incorporating a subsequent process
K J Brodbeck et al.
Journal of controlled release : official journal of the Controlled Release Society, 62(3), 333-344 (1999-10-21)
The role of solvent properties and bath-side composition on the phase inversion dynamics and in vitro protein release kinetics of polylactic-co-glycolic acid (PLGA) solutions has been examined using dark ground imaging, in vitro release rate, and SEM techniques. Thermodynamic phase
Ajit Dhananjay Jagtap et al.
European journal of medicinal chemistry, 85, 268-288 (2014-08-05)
A series of 6-acylureido derivatives containing a 3-(pyrrol-2-ylmethylidene)indolin-2-one scaffold were synthesized as potential dual Aurora B/FLT3 inhibitors by replacing the 6-arylureido moiety in 6-arylureidoindolin-2-one-based multi-kinase inhibitors. (Z)-N-(2-(pyrrolidin-1-yl)ethyl)-5-((6-(3-(2-fluoro-4-methoxybenzoyl)ureido)-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (54) was identified as a dual Aurora B/FLT3 inhibitor (IC50 = 0.4 nM and 0.5 nM, respectively).
Hsiao-Chun Wang et al.
European journal of medicinal chemistry, 84, 312-334 (2014-07-19)
Bioisosteric replacement of acylureido moiety in 6-acylureido-3-pyrrolylmethylidene-2-oxoindoline derivatives resulted in a series of malonamido derivatives with indolin-2-one scaffold (11-14). Further conformational restrictions of the malonamido moiety led to 2-oxo-1,2-dihydropyridine (21-25) or a 4-oxo-1,4-dihydropyridine derivatives (31-36). 4-Oxo-1,4-dihydropyridine derivatives were more potent
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持